chlorpromazine has been researched along with Disease Exacerbation in 8 studies
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One-hundred and sixty individuals with treatment-naive, first episode schizophrenia or schizophreniform disorder in a mental health centre in Beijing, China were randomised to clozapine or chlorpromazine treatment for up to 2 years,followed by up to an additional 7 years of naturalistic treatment." | 9.15 | Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. ( Duan, N; Girgis, RR; Jiang, H; Li, K; Li, X; Lieberman, JA; Niu, Y; Phillips, MR; Wu, C, 2011) |
| "One-hundred and sixty individuals with treatment-naive, first episode schizophrenia or schizophreniform disorder in a mental health centre in Beijing, China were randomised to clozapine or chlorpromazine treatment for up to 2 years,followed by up to an additional 7 years of naturalistic treatment." | 5.15 | Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. ( Duan, N; Girgis, RR; Jiang, H; Li, K; Li, X; Lieberman, JA; Niu, Y; Phillips, MR; Wu, C, 2011) |
| "Patients with Down syndrome are at high risk for early Alzheimer's disease." | 1.29 | Dementia and Down syndrome. ( Shank, JC; Tyler, CV, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Plaze, M | 1 |
| Attali, D | 1 |
| Petit, AC | 1 |
| Blatzer, M | 1 |
| Simon-Loriere, E | 1 |
| Vinckier, F | 1 |
| Cachia, A | 1 |
| Chrétien, F | 1 |
| Gaillard, R | 1 |
| Basta-Kaim, A | 1 |
| Szczęsny, E | 1 |
| Leśkiewicz, M | 1 |
| Głombik, K | 1 |
| Slusarczyk, J | 1 |
| Budziszewska, B | 1 |
| Regulska, M | 1 |
| Kubera, M | 1 |
| Nowak, W | 1 |
| Wędzony, K | 1 |
| Lasoń, W | 1 |
| Lee, TY | 1 |
| Kim, SN | 1 |
| Correll, CU | 1 |
| Byun, MS | 1 |
| Kim, E | 1 |
| Jang, JH | 1 |
| Kang, DH | 1 |
| Yun, JY | 1 |
| Kwon, JS | 1 |
| Gillman, K | 1 |
| Girgis, RR | 1 |
| Phillips, MR | 1 |
| Li, X | 1 |
| Li, K | 1 |
| Jiang, H | 1 |
| Wu, C | 1 |
| Duan, N | 1 |
| Niu, Y | 1 |
| Lieberman, JA | 1 |
| Schilling, G | 1 |
| Savonenko, AV | 1 |
| Coonfield, ML | 1 |
| Morton, JL | 1 |
| Vorovich, E | 1 |
| Gale, A | 1 |
| Neslon, C | 1 |
| Chan, N | 1 |
| Eaton, M | 1 |
| Fromholt, D | 1 |
| Ross, CA | 1 |
| Borchelt, DR | 1 |
| Singh, D | 1 |
| Forlano, R | 1 |
| Athey, R | 1 |
| Tyler, CV | 1 |
| Shank, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia[NCT02796859] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for chlorpromazine and Disease Exacerbation
| Article | Year |
|---|---|
Repurposing chlorpromazine to treat COVID-19: The reCoVery study.
Topics: Antiviral Agents; Anxiety; Betacoronavirus; Blood-Brain Barrier; Chlorpromazine; Clathrin-Coated Ves | 2020 |
Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial.
Topics: Adolescent; Adult; Antipsychotic Agents; China; Chlorpromazine; Clozapine; Disease Progression; Doub | 2011 |
6 other studies available for chlorpromazine and Disease Exacerbation
| Article | Year |
|---|---|
Maternal immune activation leads to age-related behavioral and immunological changes in male rat offspring - the effect of antipsychotic drugs.
Topics: Age Factors; Aging; Animals; Antipsychotic Agents; Behavior, Animal; Cell Proliferation; Cells, Cult | 2012 |
Symptomatic and functional remission of subjects at clinical high risk for psychosis: a 2-year naturalistic observational study.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Chlorpromazine; Cohort Studies; Di | 2014 |
In response to Morris et al.'s "Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine".
Topics: Antipsychotic Agents; Benzodiazepines; Bromocriptine; Chlorpromazine; Disease Progression; Dopamine | 2009 |
Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice.
Topics: Acetamides; Animals; Celecoxib; Chlorpromazine; Coenzymes; Cyclooxygenase Inhibitors; Disease Models | 2004 |
Neuroleptic malignant syndrome and catatonia in a patient with dementia.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catatonia; Chlorpromazine; Choline | 2008 |
Dementia and Down syndrome.
Topics: Adult; Alzheimer Disease; Antipsychotic Agents; Chlorpromazine; Disease Progression; Down Syndrome; | 1996 |